Nutriband (NTRB)
Market Price (6/23/2026): $3.025 | Market Cap: $36.8 MilSector: Health Care | Industry: Biotechnology
Nutriband (NTRB)
Market Price (6/23/2026): $3.025Market Cap: $36.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -80%, 3Y Excs Rtn is -54% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.96 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -453% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -25%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.0%, Rev Chg QQuarterly Revenue Change % is -35% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 179% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -242%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -242% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -26% Key risksNTRB key risks include [1] its ability to obtain FDA approval for its lead AVERSA™ Fentanyl patch, Show more. |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -80%, 3Y Excs Rtn is -54% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.96 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -453% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -25%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.0%, Rev Chg QQuarterly Revenue Change % is -35% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 179% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -242%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -242% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -26% |
| Key risksNTRB key risks include [1] its ability to obtain FDA approval for its lead AVERSA™ Fentanyl patch, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Nutriband (NTRB) stock has lost about 30% since 2/28/2026 because of the following key factors:
1. Continued lack of commercial revenue and uncertain clinical timelines for its lead abuse-deterrent fentanyl patch, AVERSA Fentanyl, dampened investor enthusiasm despite a narrower loss.
Nutriband reported no revenue for fiscal Q1 2026, which ended April 30, 2026, consistent with its pre-commercial development stage. Despite the company reporting a significantly narrower net loss of $0.08 per share for fiscal Q1 2026, exceeding consensus estimates by 95.85%, shares declined 4.25% on May 28, 2026. This suggests investors focused on the ongoing absence of commercial revenue and unclear clinical timelines rather than the improved earnings per share. While Nutriband selected a commercial brand name for AVERSA Fentanyl in March 2026, indicating progress, the product remains in development and awaits FDA approval.
2. A challenging macroeconomic environment for early-stage biotech companies, characterized by a preference for "proof over promise" and reduced early-stage funding, negatively impacted Nutriband.
In fiscal Q1 2026, the life science sector demanded "durable business models and clearer commercialization paths" from companies. Smaller and mid-cap biotech names, like Nutriband, continued to trade below historical averages, and the ability to raise capital remained difficult due to higher interest rates and tighter capital markets. Early-stage funding for biotech companies declined in fiscal Q1 2026, with seed and Series A deals totaling $2.3 billion, down from $3.7 billion in fiscal Q1 2025.
Show more
Nutriband (NTRB) stock has lost about 30% since 2/28/2026 because of the following key factors:
1. Continued lack of commercial revenue and uncertain clinical timelines for its lead abuse-deterrent fentanyl patch, AVERSA Fentanyl, dampened investor enthusiasm despite a narrower loss.
Nutriband reported no revenue for fiscal Q1 2026, which ended April 30, 2026, consistent with its pre-commercial development stage. Despite the company reporting a significantly narrower net loss of $0.08 per share for fiscal Q1 2026, exceeding consensus estimates by 95.85%, shares declined 4.25% on May 28, 2026. This suggests investors focused on the ongoing absence of commercial revenue and unclear clinical timelines rather than the improved earnings per share. While Nutriband selected a commercial brand name for AVERSA Fentanyl in March 2026, indicating progress, the product remains in development and awaits FDA approval.
2. A challenging macroeconomic environment for early-stage biotech companies, characterized by a preference for "proof over promise" and reduced early-stage funding, negatively impacted Nutriband.
In fiscal Q1 2026, the life science sector demanded "durable business models and clearer commercialization paths" from companies. Smaller and mid-cap biotech names, like Nutriband, continued to trade below historical averages, and the ability to raise capital remained difficult due to higher interest rates and tighter capital markets. Early-stage funding for biotech companies declined in fiscal Q1 2026, with seed and Series A deals totaling $2.3 billion, down from $3.7 billion in fiscal Q1 2025.
3. A decline in existing contract manufacturing revenue streams further contributed to investor concerns.
Nutriband's sales for fiscal Q1 2026 were $0.433399 million, a decrease compared to $0.667432 million in the same period a year prior. This decline in contract manufacturing revenue added to the financial pressure on the company, which is still in the pre-commercial development stage for its pharmaceutical pipeline.
Show less
Stock Movement Drivers
Fundamental Drivers
The -30.0% change in NTRB stock from 2/28/2026 to 6/22/2026 was primarily driven by a -20.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282026 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.44 | 3.11 | -30.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | -20.9% |
| P/S Multiple | 23.5 | 21.0 | -10.7% |
| Shares Outstanding (Mil) | 12 | 12 | -0.8% |
| Cumulative Contribution | -30.0% |
Market Drivers
2/28/2026 to 6/22/2026| Return | Correlation | |
|---|---|---|
| NTRB | -30.0% | |
| Market (SPY) | 8.8% | 27.5% |
| Sector (XLV) | -5.9% | 29.3% |
Fundamental Drivers
The -37.1% change in NTRB stock from 11/30/2025 to 6/22/2026 was primarily driven by a -30.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 11302025 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.95 | 3.11 | -37.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 2 | -30.1% |
| P/S Multiple | 21.5 | 21.0 | -2.5% |
| Shares Outstanding (Mil) | 11 | 12 | -7.7% |
| Cumulative Contribution | -37.1% |
Market Drivers
11/30/2025 to 6/22/2026| Return | Correlation | |
|---|---|---|
| NTRB | -37.1% | |
| Market (SPY) | 9.5% | 15.1% |
| Sector (XLV) | -4.0% | 13.3% |
Fundamental Drivers
The -52.2% change in NTRB stock from 5/31/2025 to 6/22/2026 was primarily driven by a -30.4% change in the company's P/S Multiple.| (LTM values as of) | 5312025 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.50 | 3.11 | -52.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | -24.8% |
| P/S Multiple | 30.2 | 21.0 | -30.4% |
| Shares Outstanding (Mil) | 11 | 12 | -8.5% |
| Cumulative Contribution | -52.2% |
Market Drivers
5/31/2025 to 6/22/2026| Return | Correlation | |
|---|---|---|
| NTRB | -52.2% | |
| Market (SPY) | 27.7% | 18.6% |
| Sector (XLV) | 15.2% | 9.0% |
Fundamental Drivers
The 9.5% change in NTRB stock from 5/31/2023 to 6/22/2026 was primarily driven by a 95.5% change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.84 | 3.11 | 9.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | -13.3% |
| P/S Multiple | 10.7 | 21.0 | 95.5% |
| Shares Outstanding (Mil) | 8 | 12 | -35.3% |
| Cumulative Contribution | 9.5% |
Market Drivers
5/31/2023 to 6/22/2026| Return | Correlation | |
|---|---|---|
| NTRB | 9.5% | |
| Market (SPY) | 85.1% | 12.4% |
| Sector (XLV) | 23.4% | 13.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NTRB Return | -6% | -58% | -36% | 103% | -4% | -36% | -69% |
| Peers Return | -11% | -36% | 104% | 25% | 32% | 27% | 143% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| NTRB Win Rate | 17% | 33% | 50% | 50% | 33% | 33% | |
| Peers Win Rate | 42% | 38% | 62% | 50% | 58% | 75% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| NTRB Max Drawdown | -71% | -72% | -61% | -58% | -59% | -42% | |
| Peers Max Drawdown | -40% | -52% | -39% | -21% | -32% | -21% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VTRS, AMRX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/22/2026 (YTD)
How Low Can It Go
| Event | NTRB | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -34.3% | -18.8% |
| % Gain to Breakeven | 52.1% | 23.1% |
| Time to Breakeven | 53 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -15.6% | -7.8% |
| % Gain to Breakeven | 18.5% | 8.5% |
| Time to Breakeven | 8 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -50.6% | -9.5% |
| % Gain to Breakeven | 102.6% | 10.5% |
| Time to Breakeven | 153 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -51.2% | -6.7% |
| % Gain to Breakeven | 104.9% | 7.1% |
| Time to Breakeven | 31 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -70.2% | -24.5% |
| % Gain to Breakeven | 235.6% | 32.4% |
| Time to Breakeven | 763 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -25.0% | -33.7% |
| % Gain to Breakeven | 33.3% | 50.9% |
| Time to Breakeven | 1918 days | 140 days |
In The Past
Nutriband's stock fell -34.3% during the 2025 US Tariff Shock. Such a loss loss requires a 52.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | NTRB | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -34.3% | -18.8% |
| % Gain to Breakeven | 52.1% | 23.1% |
| Time to Breakeven | 53 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -50.6% | -9.5% |
| % Gain to Breakeven | 102.6% | 10.5% |
| Time to Breakeven | 153 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -51.2% | -6.7% |
| % Gain to Breakeven | 104.9% | 7.1% |
| Time to Breakeven | 31 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -70.2% | -24.5% |
| % Gain to Breakeven | 235.6% | 32.4% |
| Time to Breakeven | 763 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -25.0% | -33.7% |
| % Gain to Breakeven | 33.3% | 50.9% |
| Time to Breakeven | 1918 days | 140 days |
In The Past
Nutriband's stock fell -34.3% during the 2025 US Tariff Shock. Such a loss loss requires a 52.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Nutriband (NTRB)
Nutriband Inc. (NTRB) is a pharmaceutical company specializing in the development of transdermal drug delivery systems. Based in Orlando, Florida, the company focuses on creating innovative products administered via skin patches, with a particular emphasis on addressing critical needs in pain management and pharmaceutical safety.
The company's lead product in development is an abuse-deterrent fentanyl transdermal system, an extended-release patch designed to help clinicians and patients manage chronic pain more safely and effectively. In addition to its proprietary pipeline, Nutriband has a license agreement for the RAMBAM Closed System Transfer Devices, which are used to ensure the secure and contained transfer of hazardous drugs in clinical settings. These offerings position Nutriband to serve the healthcare market, including patients suffering from chronic pain and healthcare professionals seeking safer drug administration and handling solutions.
AI Analysis | Feedback
Imagine them as the **Insulet** (known for its Omnipod insulin pump) of pain patches, focused on developing innovative transdermal systems for safer drug delivery.
They're a specialized pharmaceutical R&D company, like a focused, early-stage division of **Johnson & Johnson** or **Pfizer**, but solely dedicated to creating advanced, abuse-deterrent drug patches for chronic pain.
AI Analysis | Feedback
- Abuse deterrent fentanyl transdermal system: An extended-release transdermal fentanyl product designed for managing chronic pain while deterring abuse.
- RAMBAM Closed System Transfer Devices: Medical devices for safely transferring substances, developed under a license agreement.
AI Analysis | Feedback
Nutriband Inc. (NTRB) is a clinical-stage pharmaceutical company focused on developing transdermal drug products and medical devices. Based on the provided background information, the company's lead product, an abuse-deterrent fentanyl transdermal system, is currently in development. The RAMBAM Closed System Transfer Devices, developed under a license agreement with Rambam Med-Tech Ltd., are also in development.
As a development-stage company, Nutriband Inc. does not currently have major commercial customers for the sale of its pharmaceutical products or devices, as these products are not yet commercially available on the market. Pharmaceutical development companies typically focus on research, development, clinical trials, and securing regulatory approvals before initiating commercial sales and establishing a customer base.
AI Analysis | Feedback
AI Analysis | Feedback
Gareth Sheridan, Founder and Chief Executive Officer
Gareth Sheridan is an award-winning entrepreneur and the founder of Nutriband Inc.. He founded Nutriband Ltd. in Dublin in 2012 and subsequently established Nutriband Inc. in the United States. Sheridan led the company to a Nasdaq listing in 2021. In addition to his role at Nutriband, he is also an independent consultant for several companies and a private investor. He returned to the CEO position in October 2025 after a brief leave.
Gerald Goodman, Chief Financial Officer
Gerald Goodman has served as Nutriband's chief accounting officer since July 31, 2018, and became the Director of Finance/CFO on September 1, 2020.
Serguei Melnik, Founder and President
Serguei Melnik is a founder of Nutriband Inc. and currently serves as its President. He has been involved in general business consulting for companies in the U.S. financial markets. Mr. Melnik temporarily took over as interim CEO from August 10 to October 27, 2025.
Dr. Alan Smith, Chief Operating Officer and President of 4P Therapeutics
Dr. Alan Smith serves as the Chief Operating Officer of Nutriband and President of its subsidiary, 4P Therapeutics. Nutriband acquired 4P Therapeutics in 2018, an acquisition that brought the proprietary AVERSA™ abuse-deterrent transdermal technology to the company.
Dr. Jeff Patrick, Chief Scientific Officer
Dr. Jeff Patrick is the Chief Scientific Officer of Nutriband Inc. He also currently serves as the Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center.
AI Analysis | Feedback
The key risks to Nutriband Inc. (NTRB) primarily revolve around the challenging landscape of pharmaceutical development and commercialization.
-
Regulatory Approval and Commercialization of AVERSA Fentanyl: Nutriband's lead product, AVERSA Fentanyl, an abuse-deterrent transdermal fentanyl system, is currently under development, and its future success is contingent on obtaining regulatory approval from the FDA. The company needs to successfully complete clinical testing, secure patent protection for its abuse-deterrent technology, and obtain the necessary financing to advance through the regulatory process and ultimately market the product in the United States and other countries. Despite ongoing progress, including meetings with the FDA and a targeted NDA submission, there are inherent uncertainties and significant challenges associated with pharmaceutical product development and regulatory approval.
-
Financial Performance and Funding: Nutriband has consistently incurred substantial net losses, indicating ongoing operational challenges despite some revenue growth. The company experiences increased cash burn from operations due to significant development costs, necessitating a reliance on external funding sources for its product initiatives. While Nutriband demonstrates strong liquidity and a low debt-to-equity ratio, its profitability metrics, such as negative operating and net margins, highlight difficulties in generating returns for shareholders. The need for continuous capital infusion to support product development and the potential implications of financing strategies, such as preferred stock dividends tied to future product approvals, underscore financial stability as a key risk.
-
Competition and Market Acceptance: Nutriband operates in competitive markets for both its transdermal pharmaceutical products and its licensed Closed System Transfer Devices (CSTDs). The success of AVERSA Fentanyl depends on its ability to gain market acceptance against existing pain management solutions, even with its abuse-deterrent properties. For the RAMBAM Closed System Transfer Devices, the market includes established players, and challenges such as high integration costs and limited compatibility with certain medications could hinder adoption. The general competitive landscape and the ability to effectively market newly developed products are frequently cited risks in the company's forward-looking statements.
AI Analysis | Feedback
AI Analysis | Feedback
Nutriband Inc. operates in two primary markets with its key products:
Abuse-Deterrent Fentanyl Transdermal System (AVERSA™ Fentanyl)
Nutriband's lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system, has the potential to reach peak annual U.S. sales of $80 million to $200 million. This product is designed to be the world's first abuse-deterrent opioid patch. The broader global transdermal patches market was valued at approximately USD 7.84 billion in 2024 and is projected to grow to USD 11.50 billion by 2032. Within this, the fentanyl transdermal patch segment held the largest market share, around 44%, in 2024. The global fentanyl market size is expected to be valued at US$2.5 billion in 2026 and reach US$3.5 billion by 2033.
RAMBAM Closed System Transfer Devices (CSTD)
The global market for Closed System Transfer Devices (CSTD) is estimated to be USD 1.62 billion in 2026, with projections indicating growth to USD 2.97 billion by 2031, at a compound annual growth rate (CAGR) of 12.98% from 2026 to 2031. Another estimate placed the global CSTD market at US$1.49 billion in 2025, with a projected growth to US$2.09 billion by 2030 at a CAGR of 7.0%. North America is a significant region within this market, holding a 42.84% share in 2025 and dominating with a 43.5% revenue share in 2024. The North American CSTD market is expected to reach US$2.5 billion by 2029, growing at a CAGR of 14.5% during the forecast period.
AI Analysis | Feedback
Nutriband Inc. (NASDAQ: NTRB) is poised for future revenue growth over the next two to three years, driven by the anticipated commercialization of its lead pharmaceutical products, expansion of its abuse-deterrent technology platform, and continued growth in its contract manufacturing services.
Here are the key drivers of future revenue growth:
- Commercialization of AVERSA Fentanyl: Nutriband's lead product, AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal system, is a primary growth driver. The company has made significant progress, targeting a New Drug Application (NDA) submission in 2025. AVERSA Fentanyl is being developed via a 505(b)(2) regulatory pathway, requiring only a single Phase 1 Human Abuse Potential study, which is expected to expedite the approval process. Market analysis projects potential peak annual sales for AVERSA Fentanyl to range between $80 million and $200 million. Nutriband has partnered with Kindeva Drug Delivery for commercial manufacturing scale-up, further positioning it for market entry.
- Advancement of AVERSA Buprenorphine and Pipeline Expansion: Beyond AVERSA Fentanyl, Nutriband is advancing AVERSA Buprenorphine, another abuse-deterrent transdermal application, which is projected to achieve peak annual sales of up to $130 million upon approval. The company also plans to expand its AVERSA platform to other high-potential transdermal applications, including methylphenidate, aiming to establish a new safety standard for opioids and other drugs of abuse.
- Growth in Kinesiology Tape Contract Manufacturing: The company's Pocono Pharma subsidiary is continually expanding its kinesiology tape contract manufacturing services. This segment has already demonstrated strong performance, with Nutriband reporting significant year-over-year revenue increases from these services. Pocono-manufactured products are increasingly available in major retail chains such as Target, Walmart, Walgreens, and CVS. Additionally, Nutriband has an exclusive supplier agreement with Fit For Life Group, further bolstering this revenue stream.
AI Analysis | Feedback
Share Repurchases
- Nutriband Inc. authorized a share repurchase program to buy back up to $1,000,000 of its common stock, announced on September 16, 2024.
Share Issuance
- In July 2025, Nutriband issued a 25% Preferred Stock dividend to existing shareholders, with one preferred share granted for every four shares of common stock held, convertible to common stock upon FDA approval of AVERSA Fentanyl.
- Warrants issued during the company's October 1, 2021, IPO, with a strike price of $6.43 and totaling 91,0904, are set to expire on October 1, 2026, representing a potential capital inflow of $5,856,112 if all are exercised.
- Shareholders approved an amendment on January 24, 2026, to increase the number of authorized preferred shares from 10,000,000 to 20,000,000.
Outbound Investments
- Nutriband entered an agreement to sell a 90% interest in its subsidiary, Pocono Pharmaceutical, to EarthVision Bio for $5 million in December 2025.
- The proceeds from the Pocono Pharmaceutical sale are intended to fund the continued development of AVERSA Fentanyl.
Capital Expenditures
- Capital expenditures for the last 12 months (prior to March 2026) were -$5,324.
- The company reported $0 in capital expenditures in Q3 2026.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Can Nutriband Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 15.38 |
| Mkt Cap | 5.1 |
| Rev LTM | 3,046 |
| Op Inc LTM | 242 |
| FCF LTM | 188 |
| FCF 3Y Avg | 182 |
| CFO LTM | 306 |
| CFO 3Y Avg | 271 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.6% |
| Rev Chg 3Y Avg | -2.6% |
| Rev Chg Q | 3.9% |
| QoQ Delta Rev Chg LTM | 0.9% |
| Op Inc Chg LTM | -31.3% |
| Op Inc Chg 3Y Avg | -22.6% |
| Op Mgn LTM | 1.7% |
| Op Mgn 3Y Avg | 4.7% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 10.0% |
| CFO/Rev 3Y Avg | 9.7% |
| FCF/Rev LTM | 6.2% |
| FCF/Rev 3Y Avg | 6.5% |
Price Behavior
| Market Price | $3.11 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/16/2018 | |
| Distance from 52W High | -71.0% | |
| 50 Days | 200 Days | |
| DMA Price | $3.68 | $4.87 |
| DMA Trend | down | down |
| Distance from DMA | -15.4% | -36.2% |
| 3M | 1YR | |
| Volatility | 56.9% | 74.4% |
| Downside Capture | 266.88 | 226.91 |
| Upside Capture | 77.15 | 57.76 |
| Correlation (SPY) | 27.2% | 17.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.55 | 1.16 | 1.06 | 0.68 | 1.24 | 0.82 |
| Up Beta | 1.83 | -0.17 | 0.28 | -0.05 | -0.19 | 0.21 |
| Down Beta | -3.36 | -1.33 | -1.25 | -1.04 | 0.63 | 0.39 |
| Up Capture | 62% | 113% | 113% | 96% | 139% | 229% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 7 | 19 | 31 | 61 | 117 | 354 |
| Down Capture | 511% | 460% | 267% | 194% | 183% | 110% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 12 | 21 | 31 | 62 | 127 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NTRB | |
|---|---|---|---|---|
| NTRB | -49.6% | 71.3% | -0.68 | - |
| Sector ETF (XLV) | 14.7% | 15.0% | 0.70 | 7.8% |
| Equity (SPY) | 26.1% | 12.4% | 1.59 | 16.1% |
| Gold (GLD) | 24.1% | 27.5% | 0.77 | 3.1% |
| Commodities (DBC) | 18.5% | 18.8% | 0.77 | -5.9% |
| Real Estate (VNQ) | 11.8% | 13.8% | 0.57 | 15.7% |
| Bitcoin (BTCUSD) | -40.2% | 42.5% | -1.09 | 13.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NTRB | |
|---|---|---|---|---|
| NTRB | -6.3% | 128.5% | 0.44 | - |
| Sector ETF (XLV) | 5.5% | 14.7% | 0.19 | 12.0% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 11.1% |
| Gold (GLD) | 17.1% | 18.3% | 0.76 | 2.1% |
| Commodities (DBC) | 7.5% | 19.4% | 0.28 | 0.4% |
| Real Estate (VNQ) | 2.1% | 18.9% | 0.01 | 8.1% |
| Bitcoin (BTCUSD) | 9.4% | 54.1% | 0.37 | 6.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NTRB | |
|---|---|---|---|---|
| NTRB | 28.9% | 220.2% | 0.77 | - |
| Sector ETF (XLV) | 9.5% | 16.6% | 0.46 | 8.2% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 8.4% |
| Gold (GLD) | 12.2% | 16.1% | 0.62 | 2.0% |
| Commodities (DBC) | 6.0% | 18.0% | 0.26 | -0.2% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 5.9% |
| Bitcoin (BTCUSD) | 59.9% | 66.8% | 1.00 | 0.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 04/30/2026 | 06/11/2026 | 10-Q |
| 01/31/2026 | 04/29/2026 | 10-K |
| 10/31/2025 | 12/11/2025 | 10-Q |
| 07/31/2025 | 09/09/2025 | 10-Q |
| 04/30/2025 | 05/30/2025 | 10-Q |
| 01/31/2025 | 04/28/2025 | 10-K |
| 10/31/2024 | 12/04/2024 | 10-Q |
| 07/31/2024 | 09/03/2024 | 10-Q |
| 04/30/2024 | 05/31/2024 | 10-Q |
| 01/31/2024 | 05/01/2024 | 10-K |
| 10/31/2023 | 12/13/2023 | 10-Q |
| 07/31/2023 | 09/11/2023 | 10-Q |
| 04/30/2023 | 06/09/2023 | 10-Q |
| 01/31/2023 | 04/26/2023 | 10-K |
| 10/31/2022 | 12/02/2022 | 10-Q |
| 07/31/2022 | 09/08/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 04/30/2026 | 06/11/2026 | 10-Q |
| 01/31/2026 | 04/29/2026 | 10-K |
| 10/31/2025 | 12/11/2025 | 10-Q |
| 07/31/2025 | 09/09/2025 | 10-Q |
| 04/30/2025 | 05/30/2025 | 10-Q |
| 01/31/2025 | 04/28/2025 | 10-K |
| 10/31/2024 | 12/04/2024 | 10-Q |
| 07/31/2024 | 09/03/2024 | 10-Q |
| 04/30/2024 | 05/31/2024 | 10-Q |
| 01/31/2024 | 05/01/2024 | 10-K |
| 10/31/2023 | 12/13/2023 | 10-Q |
| 07/31/2023 | 09/11/2023 | 10-Q |
| 04/30/2023 | 06/09/2023 | 10-Q |
| 01/31/2023 | 04/26/2023 | 10-K |
| 10/31/2022 | 12/02/2022 | 10-Q |
| 07/31/2022 | 09/08/2022 | 10-Q |
| 04/30/2022 | 05/31/2022 | 10-Q |
| 01/31/2022 | 04/29/2022 | 10-K |
| 10/31/2021 | 12/14/2021 | 10-Q |
| 07/31/2021 | 09/03/2021 | 10-Q |
| 04/30/2021 | 06/14/2021 | 10-Q |
| 01/31/2021 | 04/02/2021 | 10-K |
| 10/31/2020 | 12/15/2020 | 10-Q |
| 07/31/2020 | 09/11/2020 | 10-Q |
| 04/30/2020 | 06/04/2020 | 10-Q |
| 01/31/2020 | 04/14/2020 | 10-K |
| 10/31/2019 | 12/12/2019 | 10-Q |
| 07/31/2019 | 09/13/2019 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.